RGD-Modified Angiogenesis Inhibitor HM-3 Dose: Dual Function during Cancer Treatment

详细信息    查看全文

• 作者：Hanmei Xu ; Li Pan ; Yinling Ren ; Yongjing Yang ; Xiaofeng Huang ; Zhendong Liu
• 刊名：Bioconjugate Chemistry
• 出版年：2011
• 出版时间：July 20, 2011
• 年：2011
• 卷：22
• 期：7
• 页码：1386-1393
• 全文大小：1008K
• 年卷期：v.22,no.7(July 20, 2011)
• ISSN：1520-4812

文摘

In the present study, we have undertaken pharmacodynamic studies of HM-3 in vitro and in vivo. A dual function of HM-3 with various doses was observed. HM-3 at low dose revealed obvious anticancer activity. In contrast, HM-3 at high dose had a tendency to promote tumorigenesis and tumor metastasis. Microarray analysis demonstrated that HM-3 at high dose could up-regulate the transcription of AKT1 and MEK1, which resulted in the promotion of tumorigenesis and metastasis. Therefore, the dose of angiogenesis inhibitors plays a critical role in cancer treatment. In order to achieve the ideal effect of angiogenesis inhibitor drugs on cancer treatment, a ful exploration of administration dose, frequency, and period for this kind of drugs is highly desired.